2023-507820-22-00招募中1 期
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 56
- 试验地点
- 13
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
GSM-CT
Scientific
Celgene Corp.
研究点 (13)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)Systemic Sclerosis2023-503823-24-01Celgene Corp.65
招募中
2 期
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML (Acute Myeloïd Leukemia) expressing CD19.”2023-509212-29-01Centre Hospitalier Universitaire De Lille5
招募中
2 期
DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)2024-515174-27-00Rigshospitalet20
进行中（未招募）
1 期
T cell therapy for patients with leukemia or lymphomaCD19+ B cell lymphoma or leukemiaEUCTR2013-001393-19-SEppsala university30
进行中（未招募）
1 期
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. Phase I/II clinical trial (MERMAID1)EUCTR2021-003409-23-PLMedical University of Warsaw20